WilmerHale Advises Dyne Therapeutics in its Initial Public Offering

WilmerHale Advises Dyne Therapeutics in its Initial Public Offering

News

On September 21, 2020, Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, announced the closing of its initial public offering of 14,089,314 shares of its common stock at an initial public offering price of $19.00 per share, including 1,837,736 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Dyne. The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Dyne, were approximately $268 million.

The WilmerHale team representing Dyne was led by Stuart Falber, and included Jeffries Oliver-Li, Scott Lunin, Mike Lopes, Sean Linnehan, Lauren Roberts, Ciara Baker, Bruce Manheim and Heidi Treiber.